Intellia Therapeutics Advances with FDA Priority Review for Groundbreaking CRISPR Therapy
Intellia Therapeutics secures FDA Priority Review for its CRISPR therapy, potentially transforming the treatment landscape for hereditary an…
Sernova and Seraxis Merge to Form BetaNova Biotherapeutics: A New Player in Type 1 Diabetes Treatment
Sernova and Seraxis merge to create BetaNova, a company poised to innovate in Type 1 diabetes treatment.
Merck-Moderna mRNA Cancer Vaccine Hits Phase 3 Melanoma Endpoints, Boosting Both Stocks' Oncology Pipelines
The INTerpath-001 Phase 3 trial of intismeran autogene plus KEYTRUDA met co-primary endpoints in melanoma, de-risking the mRNA oncology plat…
Merck and Moderna's mRNA Cancer Vaccine Hits Phase 3 Milestone — What It Means for MRK and MRNA Investors
Merck and Moderna's Phase 3 INTerpath-001 trial met both primary endpoints for melanoma, validating mRNA neoantigen technology and opening m…
Royalty Pharma Shares Under Pressure as Novartis' Pelacarsen Phase 3 HORIZON Trial Disappoints
RPRX's royalty stake in pelacarsen suffers as Novartis' Phase 3 cardiovascular outcomes trial misses key endpoints, pressuring net present v…
Merck and Moderna's mRNA Cancer Vaccine Scores Phase 3 Win — What It Means for MRK and MRNA Investors
The Phase 3 INTerpath-001 trial of Moderna's personalized mRNA cancer vaccine plus Merck's Keytruda met both co-primary endpoints in high-ri…
Moderna and Merck's mRNA Cancer Vaccine Trial: A Turning Point for Biotech Investors
The Phase 3 INTerpath-001 trial results could reshape oncology market dynamics for Moderna and Merck, opening new revenue streams.
Merck and Moderna's mRNA Vaccine Triumphs in Melanoma Phase 3 Trials
Merck and Moderna's Phase 3 trial results demonstrate significant advancements in melanoma treatment, impacting stock performance and oncolo…
Ionis Pharmaceuticals Secures FDA Approval for Groundbreaking Zanvastro Treatment
Ionis Pharmaceuticals' Zanvastro receives FDA approval, marking a significant milestone in the treatment of Alexander disease.
AbbVie Expands Immunology Pipeline with $11 Billion Acquisition of Apogee Therapeutics
AbbVie makes a bold move, acquiring Apogee Therapeutics for $11 billion, signaling a strategic push in immunology.
Moderna's 177% Surge: The Successful Phase 3 Trial That Could Transform Oncology
Moderna's recent Phase 3 trial success has triggered a 177% stock surge, signaling a potential new era in oncology investment.
Ultragenyx's Dramatic Stock Plunge: What It Means for Rare Disease Biotech Investors
Ultragenyx's stock plummeted 44.7% following the failure of a pivotal trial, raising questions for biotech investors.







